ALLERGY THER. PLC LS-001
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
ALLERGY THER. PLC LS-001 (HHU) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALLERGY THER. PLC LS-001 (HHU) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALLERGY THER. PLC LS-001 - Net Assets Trend (None–None)
This chart illustrates how ALLERGY THER. PLC LS-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALLERGY THER. PLC LS-001 (None–None)
The table below shows the annual net assets of ALLERGY THER. PLC LS-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALLERGY THER. PLC LS-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALLERGY THER. PLC LS-001 Competitors by Market Cap
The table below lists competitors of ALLERGY THER. PLC LS-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ouro Fino Saúde Animal Participações S.A
SA:OFSA3
|
$32.46 Million |
|
Mutual-Tek Industries Co., Ltd.
TWO:6407
|
$32.46 Million |
|
Shangri La Hotels Malaysia Bhd
KLSE:5517
|
$32.47 Million |
|
Changhae Ethanol Co. Ltd
KQ:004650
|
$32.47 Million |
|
Cellumed Co. Ltd
KQ:049180
|
$32.46 Million |
|
Romerike Sparebank
OL:ROMER
|
$32.44 Million |
|
Careium AB
ST:CARE
|
$32.44 Million |
|
District Metals Corp.
PINK:DMXCF
|
$32.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALLERGY THER. PLC LS-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALLERGY THER. PLC LS-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALLERGY THER. PLC LS-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALLERGY THER. PLC LS-001's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALLERGY THER. PLC LS-001 (HHU) | €- | N/A | N/A | $32.46 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |